Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial

Glenn M. Stewart, Bruce D. Johnson, Dennis L. Sprecher, Yogesh N.V. Reddy, Masaru Obokata, Steven Goldsmith, Brad Bart, Anna Oughton, Christina Fillmore, David J. Behm, Barry A. Borlaug

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Aims: Lung congestion in patients with heart failure (HF) has traditionally been treated using interventions that reduce pulmonary capillary hydrostatic pressure. The transient receptor potential vanilloid 4 (TRPV4) channel regulates fluid transit across the pulmonary capillary-interface, and represents a novel target to reduce lung water, independent of pulmonary capillary hypertension. This pilot study examined the safety and potential efficacy of TRPV4 blockade as a novel treatment for HF. Methods and results: In this randomized, double-blind, placebo-controlled crossover pilot trial, 11 subjects with chronic, compensated HF were treated with a novel TRPV4 antagonist (GSK2798745) or placebo. The primary endpoint was lung diffusing capacity for carbon monoxide (DLCO) after 7 days of treatment with GSK2798745 as compared to placebo. Secondary endpoints included additional diffusion parameters, spirometry and safety assessments. Compared to placebo, treatment with GSK2798745 resulted in a trend to improvement in DLCO (placebo: −0.336 mL/mmHg/min; GSK2798745: +0.458 mL/mmHg/min; treatment difference: +0.793 mL/mmHg/min; 95% confidence interval: −0.925 to 2.512) that was not statistically significant. GSK2798745 was well-tolerated with no serious adverse events. Conclusion: In this pilot trial, GSK2798745 was found to be safe and well-tolerated, with a trend toward improved gas transfer. Further investigation is warranted in larger studies to determine whether treatment with TRPV4 antagonists or alternative treatments targeting capillary permeability might be effective to improve lung congestion, pulmonary gas transfer and clinical status in patients with acute or chronic HF.

Original languageEnglish (US)
Pages (from-to)1641-1645
Number of pages5
JournalEuropean Journal of Heart Failure
Issue number9
StatePublished - Sep 1 2020


  • Extravascular lung water
  • Lung diffusion
  • Pharmacotherapy
  • Transient receptor potential vanilloid 4

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial'. Together they form a unique fingerprint.

Cite this